A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer

Ronald Feld, Margaret M. Woo, Natasha Leighl, Frances A. Shepherd, J. Thaddeus Beck, Lihui Zhao, Lucien Gazi, Thomas Hengelage, Maria Grazia Porro, Asha Nayak

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Purpose: Panobinostat is a potent oral pan-deacetylase inhibitor with promising clinical activity in hematologic malignancies. Panobinostat was shown to inhibit CYP2D6 activity in vitro; thus understanding the magnitude of the potential clinical inhibition of panobinostat on co-medications that are CYP2D6 substrates becomes important. Methods: This study evaluated the effects of co-administration of panobinostat with a sensitive CYP2D6 substrate, dextromethorphan (DM), in patients with advanced cancer who have functional CYP2D6 genes. Patients received 60 mg DM alone on day 1, panobinostat at 20 mg alone on days 3 and 5, and both agents on day 8. Plasma concentrations of DM and its metabolite dextrorphan (DX) were determined by liquid chromatography-tandem mass spectrometry following serial blood collections on day 1 (DM alone) and day 8 (in combination with panobinostat). Results: Panobinostat increased DM exposure by 64 % [geometric mean ratio (GMR), 1.64 (90 % confidence interval (CI), 1.17-2.31)] and DX exposure by 29 % (GMR, 1.29 [90 % CI, 1.10-1.51]). These results indicated that panobinostat weakly inhibited a sensitive CYP2D6 substrate in cancer patients by increasing DM exposure by less than twofold. Conclusion: Safety monitoring of sensitive CYP2D6 substrates with narrow therapeutic index is recommended when co-administering with panobinostat in future clinical practice.

Original languageEnglish (US)
Pages (from-to)747-755
Number of pages9
JournalCancer Chemotherapy and Pharmacology
Volume72
Issue number4
DOIs
Publication statusPublished - Oct 1 2013

    Fingerprint

Keywords

  • CYP2D6
  • Dextromethorphan
  • Panobinostat
  • Pharmacokinetics

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this